TriSalus Life Sciences is focusing on its TriNav infusion system, which could drive future growth. However, the current financial loss and low cash reserves pose risks, potentially requiring fundraising. The company's optimism about future cash flow is a positive sign, but the immediate impact on stock price is neutral due to these mixed factors.